Skip to content
  • About
    • Supporter
    • Expert Index
    • Editorial Board
    • Editorial Team
    • Editorial Policy
  • Contact
  • Sign up

Visit

vjhemonc logo
VJRegenMed
Logo
  • Home (current)
  • Specialties
    Hematology
    Oncology
    Musculoskeletal Disorder
    Rare Disease
    Metabolic Disorder
    Cardiovascular Disease
    Ophthalmology
    Neurology
    Infectious Disease
    View all Specialties
  • Technologies
    Cell Therapy
    MSC
    iPSC
    Gene Therapy
    Genome Editing
    Extracellular Vesicles
    CAR-T Therapy
    TCR Therapy
    Tissue-Engineering & Biomaterials
    View all Technologies
  • Topics
    Treatment
    Immuno-Oncology
    Trial Updates
    Perspectives
    Manufacturing
    COVID-19
    View all Topics
  • Conferences
    ASH 2022
    TCT 2022
    Meeting on the Med 2022
    ICLE 2022
    Advanced Therapies Week 2022
    TERMIS 2021
    ESGCT 2021
    Meeting on the Mesa 2021
    Advanced Therapies 2021
    View all Conferences
    • About
      • Supporter
      • Expert Index
      • Editorial Board
      • Editorial Team
      • Editorial Policy
    • Contact
    • Sign up

tumor microenvironment

Targeting neoantigens in multiple myeloma with CAR T-cell 5:56
Targeting neoantigens in multiple myeloma with CAR T-cell
Angela Krackhard • 6 Apr 2022
Unanswered questions in developing engineered T cells for solid tumors 2:35
Unanswered questions in developing engineered T cells for solid tumors
Elvira D’Ippolito • 31 Mar 2022
Trends and innovations within the advanced therapy sector 1:12
Trends and innovations within the advanced therapy sector
Bruce Levine • 27 Jan 2022
Mechanisms of resistance to CAR T-cell therapies 5:09
Mechanisms of resistance to CAR T-cell therapies
John Rossi • 26 Aug 2021
Genome editing to address challenges with adoptive T-cell therapy 3:02
Genome editing to address challenges with adoptive T-cell therapy
Chiara Bonini • 22 Nov 2021
Developing novel TCR-based T cell products for cancer therapy 3:13
Developing novel TCR-based T cell products for cancer therapy
Chiara Bonini • 22 Nov 2021
Liquid vs solid tumor strategies in cell therapy 2:17
Liquid vs solid tumor strategies in cell therapy
Kanya Rajangam • 13 Oct 2021
The landscape of cell therapy for solid tumors 1:22
The landscape of cell therapy for solid tumors
Sven Kili • 5 Oct 2021
Selecting TCRs: understanding peptide-HLA-TCR interactions 6:05
Selecting TCRs: understanding peptide-HLA-TCR interactions
Dolores Schendel • 25 Feb 2021
Combining iNKT and CAR technology 6:34
Combining iNKT and CAR technology
Marc van Dijk • 23 Feb 2021
PD1-41BB switch receptor expression in the treatment of PD-L1-positve solid tumors 5:11
PD1-41BB switch receptor expression in the treatment of PD-L1-positve solid tumors
Dolores Schendel • 25 Feb 2021
Journal Pages
  • Specialties
  • Technologies
  • Topics
  • Conferences
Newsletter

Receive the latest news and videos from VJRegenMed via email

Sign up
Contact Us

Contact us for more information

mmp logo

Magdalen Centre
The Oxford Science Park
Oxford OX4 4GA, United Kingdom

VJRegenMed logo
The content of VJRegenMed is intended for healthcare professionals
  • Cookie Policy
  • Privacy Policy
  • Terms of Use
  • Editorial Policy